Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN

The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal of Hematology & Oncology.